This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Cell & Gene Therapy Manufacturing & Commercialization US

Early Registration Savings Deadline Expires In

  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event
September 27-30, 2022Boston Convention and Exhibition Center

Larry Weiner
VP Pharmaceutical Development & Manufacturing (CMC) at Enzyvant Therapeutics


Larry Weiner is a high energy, technical team leader with a 30-year record of motivating people and achieving results in the biopharmaceutical industry. As the Vice President of Pharmaceutical Development and Manufacturing at Enzyvant Therapeutics, Larry recently played a key role in securing FDA commercial approval for a tissue based regenerative medicine product. Immediately prior to Enzyvant Therapeutics, Larry was the Vice President of Technical Operations & CMC at Unum Therapeutics. Other experience includes engineering, program management, process development, and manufacturing leadership roles at Biogen, Sunflower Therapeutics, MassBiologics, Pfizer, Serono, Indigo Ag, and Amgen. He has led and supported cell therapy, gene therapy, biologics, oligonucleotides, tissue therapy, blood fraction & vaccines strategy development, cGMP operations, and regulatory inspections. Larry has a Bachelor of Science in Chemical Engineering from Tufts University, an MBA from Babson College, and a Masters in Bioengineering from Tufts University.

Agenda Sessions

  • Obtaining Commercial Approval for a Tissue Based Regenerative Medicine Product - A CMC Perspective